Priyanka Tiwari
Share
Suspense crime, Digital Desk : A major French pharmaceutical company, Servier, is set to significantly expand its operations in India, bringing advanced new cancer therapies to the country and establishing a new Research and Development (R&D) hub. This move signals strong confidence in India's growing healthcare market and its scientific talent pool.
The company plans to introduce cutting-edge treatments for several hard-to-treat cancers, including stomach, colorectal, and pancreatic cancer. By launching these globally recognized therapies in India, Servier aims to provide new hope and better treatment options for Indian patients battling these aggressive diseases.
Beyond just selling medicines, Servier is making a strategic investment in India's innovation ecosystem. The company plans to build an R&D center in the country to tap into its rich pool of skilled scientists and researchers. This new hub will focus on drug development and is also looking to forge partnerships with local companies through licensing deals and potential acquisitions. This will not only create high-skilled jobs but also further solidify India's position as a global pharmaceutical powerhouse.
Servier operates with a unique structure; it is governed by a non-profit foundation, which means its profits are reinvested back into research and development rather than being distributed to shareholders. This mission-driven approach underscores their long-term commitment to advancing medical science and improving patient outcomes in India and around the world.
Read More: BJP Makes History in Kerala with First Ever Local Body Leadership Win
